卡培他滨片联合奥沙利铂注射剂治疗晚期结肠癌患者的临床研究

目的 观察卡培他滨片联合奥沙利铂注射剂治疗晚期结肠癌患者的临床疗效及安全性.方法 将97例晚期结肠癌患者随机分为对照组49例和试验组48例.对照组给予130 mg·m-2奥沙利铂,静脉滴注,于2～3 h内滴完,第1天;试验组在对照组治疗的基础上,给予1250 mg·m-2卡培他滨,bid,口服,第1～14天.2组患者均...

Clinical trial of capecitabine tablets combined with oxaliplatin injection in the treatment of patients with advanced colon cancer

Objective To observe the clinical efficacy and safety of capecitabine tablets combined with oxaliplatin injection in the treatment of advanced colon cancer patients.Methods A total of 97 patients with advanced colon cancer were randomly divided into control group(n=49 cases)and treatment group(n=48 cases).The control group was given 130 mg·m^-2 oxaliplati by intravenous drip within 2-3 hours on the first day.On the basis of control group,the treatment group was given 1250 mg·m^-2 capecitabine,bid,orally for day 1-14.Two groups were treated for 6 courses with 21 days per course.The clinical efficacy,serum levels of ras product p21 protein(rasP21)and cyclooxygenase-2(COX-2),and adverse drug reactions were compared between two groups.Results After treatment,the total effective rates of the treatment and control groups were 60.42%(29 cases/48 cases)and 36.73%(18 cases/49 cases)with significant difference(P<0.05).After treatment,the main indexes of treatment and control groups were compared:rasp21 were(10.03±2.11)and(19.90±3.02)ng·mL^-1,COX-2 were(3.11±1.10)and(6.70±2.01)ng·mL^-1,the differences were statistically significant(all P<0.05).The adverse drug reactions of treatment group were leucopenia,nausea and vomiting,while those in the control group were leucopenia,nausea and vomiting.The total incidences of adverse drug reactions in the treatment and control groups were 66.67%(32 cases/48 cases)and 73.47%(36 cases/49 cases)without significant difference(P>0.05).Conclusion Capecitabine tablets combined with oxaliplatin injection have a definitive clinical efficacy in the treatment of advanced colon cancer,which can significantly reduce the levels of serum rasP21 and COX-2,without increasing the incidence of adverse drug reactions.